Best ADC (Antibody-Drug Conjugate) CDMOs in Asia
· updated as new inspection, certificate, and trial data enters the platform
14
CDMOs tracked
4
Fully scored
8
With FDA records
24
FDA inspections
46
EMA/MHRA GMP certs
Antibody-drug conjugates pair a targeting antibody with a cytotoxic payload via a chemical linker — a three-component process that crosses biologics, small-molecule, and HPAPI (high-potency API) disciplines. Manufacturing demands purpose-built containment (typically OEB-5), wet-chemistry linker-payload synthesis, and validated bioconjugation under GMP.
Selecting an ADC CDMO turns on commercial bioconjugation track record, containment level, the linker / payload chemistries already in their book of business (vc, mc, glucuronide; MMAE, MMAF, DM1, DM4, Dxd, calicheamicin, PBDs, etc.), drug-substance + drug-product capability, and clean FDA + EMA/MHRA inspections. The rankings below score each CDMO on FDA inspections, GMP certification, clinical activity, and capacity.
FDA inspection outcomes across these CDMOs: 12 NAI (no action), 12 VAI (voluntary action), 0 OAI (official action). Leading inspection & GMP sites: Denmark (23), India (12), UNITED KINGDOM (10), United States (5), Germany (4).
Last updated 2026-10-30. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
| # | CDMO | Signal Score | Quality | FDA · GMP | Capacity | Programs |
|---|---|---|---|---|---|---|
| 1 |
AG
AGC Biologics
Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP
Hiring · 35 open roles
|
78.5 | 99.8 | 4 insp · 27 GMP | Available | 2 programs |
| 2 |
PR
Piramal Pharma Solutions
Lexington, KY · Riverview, MI · Ahmedabad, IN
|
83.5 | 95.6 | 7 insp · 15 GMP | — | 0 programs |
| 3 |
WB2
WuXi Biologics
Shanghai, CN · Wuxi, CN
|
82.7 | 99.6 | 1 insp · 4 GMP | — | 0 programs |
| 4 |
SB
Samsung Biologics
Incheon, South Korea, Rockville, Maryland, USA
Hiring · 22 open roles
|
61.5 | — | — | Available | 0 programs |
| — |
Cohance Lifesciences
India
|
Profiled | — | 6 insp · 0 GMP | — | 0 programs |
| — |
Lupin Manufacturing Solutions
Mumbai, India
|
Profiled | — | 2 insp · 0 GMP | — | 0 programs |
| — |
Porton Pharma Solutions
Chongqing, China
|
Profiled | — | 1 insp · 0 GMP | — | 0 programs |
| — |
ChemExpress
Shanghai, China
|
Profiled | — | 1 insp · 0 GMP | — | 0 programs |
| — |
Levena Biopharma
Suzhou, Jiangsu, China
|
Profiled | — | — | — | 0 programs |
| — |
Formosa Laboratories
Taoyuan, Taiwan
|
Profiled | — | 2 insp · 0 GMP | — | 0 programs |
| — |
Anax Laboratories
Hyderabad, Telangana, India
|
Profiled | — | — | — | 0 programs |
| — |
Chongqing Sintaho Pharmaceutical
Chongqing, China
|
Profiled | — | — | — | 0 programs |
| — |
Hanmi Pharm
Seoul, South Korea
|
Profiled | — | — | — | 0 programs |
| — |
Huateng Pharma
Changsha, Hunan, China
|
Profiled | — | — | — | 0 programs |
What to evaluate in a ADC (Antibody-Drug Conjugate) CDMO
HPAPI containment
Look for OEB-5 (sub-microgram occupational exposure band) suites for handling cytotoxic payloads end-to-end. Containment maturity is the floor for credible commercial ADC work.
Linker-payload chemistry on file
Match the CDMO's payload + linker experience to your program. MMAE / vc-MMAE is the most common; PBDs, calicheamicin, Dxd-class topoI inhibitors, and TLR agonists each carry distinct handling and analytical demands.
Commercial bioconjugation track record
Has the CDMO conjugated a commercially-approved ADC? Track record on Polivy, Padcev, Trodelvy, Enhertu, Tivdak, Elahere, Adcetris, Mylotarg, Besponsa, Lumoxiti, Blenrep, etc. is a strong qualifying signal.
Integrated DS + DP
Bioconjugation produces ADC drug substance; you'll also need sterile fill-finish for drug product. Confirm whether the CDMO covers both or partners — both routes work, but integrated is faster on transfer.
Regulatory track record
Cross-check FDA 483 history and EMA/MHRA GMP coverage — both shown above and on each profile.
Regulatory landscape across PMDA (Japan), NMPA (China), MFDS (South Korea)
Asian biopharma manufacturing spans multiple national regulators. PMDA (Japan) is generally regarded as one of the most stringent in Asia, with GMP requirements broadly aligned with FDA and EMA. NMPA (China) has substantially strengthened its GMP framework over the past decade, and Chinese CDMOs increasingly hold FDA and EMA certifications alongside NMPA registration. MFDS (South Korea) certification is standard for Korean CDMOs. For sponsors supplying US or EU markets, the qualifying signal for an Asian CDMO is typically FDA and EMA inspection history on the specific facility — which the Signal Score's Quality Compliance pillar captures directly.
Which Asian CDMOs cover FDA (US) and EMA/MHRA (Europe) regulatory geographies?
Asian CDMOs with US FDA and European EMA/MHRA inspection history are qualified to supply global markets; those without cross-jurisdictional inspection posture are typically limited to their home-market regulatory scope. The Signal Score's Quality Compliance pillar includes FDA + EMA + MHRA data directly, so Asian CDMOs with cross-jurisdictional certification typically rank higher on this pillar than home-market-only competitors. Sponsors evaluating an Asian CDMO for a US or EU program should cross-check with the US region ranking and Europe region ranking — CDMOs appearing across regions have demonstrated multi-jurisdictional posture.
Recent US regulatory events affecting Asian CDMO selection (WuXi 1260H, BioSecure Act considerations)
Asian CDMOs — particularly Chinese-headquartered players — are subject to US regulatory events that affect sponsor risk assessment. The US Department of Defense's 1260H list (which added WuXi AppTec in June 2026) and the BioSecure Act (proposed federal legislation restricting federally-funded research and Medicare/Medicaid drug programs from working with named Chinese biotech companies) are both active considerations. CDMO Signal's platform does not encode US political risk into the Signal Score directly — the composite reflects regulatory quality, operations, financial stability, and capacity signals. Sponsors weighing an Asian CDMO for a US-supplying program should evaluate US regulatory risk separately as a distinct decision layer alongside the Signal Score-based capability assessment.
ADC (Antibody-Drug Conjugate) CDMOs — Frequently Asked Questions
Who are the top ADC (Antibody-Drug Conjugate) CDMOs?
By CDMO Signal's independent Signal Score, the top-ranked ADC (Antibody-Drug Conjugate) CDMOs include AGC Biologics, Piramal Pharma Solutions, WuXi Biologics. See the full ranked table above — scored on FDA, clinical, financial, and capacity data.
How many ADC (Antibody-Drug Conjugate) CDMOs have FDA inspection records?
CDMO Signal tracks 8 ADC (Antibody-Drug Conjugate) CDMOs with FDA inspection records and 46 EMA/MHRA GMP certificates across the group.
What's the difference between an ADC CDMO and a biologics CDMO?
A biologics CDMO makes the naked antibody (drug substance). An ADC CDMO additionally handles the cytotoxic payload synthesis and the bioconjugation step under HPAPI containment. Some large CDMOs (Lonza, Catalent) do both; others specialize in conjugation only and source the antibody from a biologics partner.
Which CDMOs have made commercially-approved ADCs?
Several CDMOs have commercial ADC track records. The rankings above show our scored ADC players — Lonza (Polivy, Padcev), Catalent (multi-program commercial conjugation), Piramal, AGC Biologics, Samsung Biologics, WuXi Biologics, Charles River — with FDA inspection and GMP detail per profile.
What HPAPI containment level should an ADC CDMO have?
OEB-5 (sub-microgram per cubic meter occupational exposure band) is the standard floor for handling MMAE, MMAF, DM1, DM4, Dxd, PBDs, and calicheamicin-class payloads. Some legacy payloads can run in OEB-4 but commercial work is OEB-5.
Related modalities